Skip to main content

Table 3. PCR-adjusted treatment response of study patients treated with artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL)

From: Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine and polymorphism in Plasmodium falciparum kelch13-propeller gene in Equatorial Guinea

Treatment responses Artesunate-amodiaquine Artemether-lumefantrine
Malabo (N = 88)
n (%)
Bata (N = 88)
n (%)
Ebibeyin (N = 88)
n (%)
Malabo (N = 50)
n (%)
Bata (N = 88)
n (%)
Ebibeyin (N = 88)
n (%)
PCR-adjusted WHO methodology
 LCF 0 0 0 0 0 0
 LPF 0 0 1 (1.4) 2 (4.9) 0 5 (7.6)
 ACPR 67 (100) 78 (100) 71 (98.6) 39 (95.1) 81 (100) 61 (92.4)
Total per-protocol 67 78 72 41 81 66
Lost follow-up/withdrawn 21 (23.9) 7 (8) 8 (9.1) 8 (16) 3 (3.4) 5 (5.7)
New infection 0 3 (3.4) 8 (9.1) 1 (2) 4 (4.5) 17 (19.3)
Kaplan Meier: cure rate 67 (100) 78 (100) 71 (98.7) 39 (95.2) 81 (100) 61 (93.7)
PCR-adjusted 2/3 algorithm
 LCF 0 0 1 (1.3) 0 0 12 (16.4)
 LPF 0 0 4 (5.3) 3 (4.9) 0 5 (7.6)
 ACPR 67 (100) 78 (100) 71 (93.4) 39 (92.9) 81 (100) 61 (83.6)
Total per-protocol 67 78 76 42 81 73
Lost follow-up/withdrawn 21 (23.9) 7 (8) 8 (9.1) 8 (16) 3 (3.4) 5 (5.7)
New infection 0 2 (2.3) 2 (2.6) 0 2 (2.3) 7 (7.9)
Undetermined 0 1 (1.1) 2 (2.6) 0 2 (2.3) 3 (3.4)
Kaplan Meier: cure rate 100 100 93.6 92.9 100 84.5